BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 19349493)

  • 1. Current treatments for advanced stage non-small cell lung cancer.
    Stinchcombe TE; Socinski MA
    Proc Am Thorac Soc; 2009 Apr; 6(2):233-41. PubMed ID: 19349493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
    de Marinis F; Rossi A; Di Maio M; Ricciardi S; Gridelli C;
    Lung Cancer; 2011 Jul; 73(1):1-10. PubMed ID: 21440325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I
    Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME).
    Schnabel PA; Smit E; Carpeño Jde C; Leśniewski-Kmak K; Aerts J; Kraaij K; Visseren-Grul C; Dyachkova Y; Taipale K; Girvan A; Moro-Sibilot D
    Lung Cancer; 2012 Dec; 78(3):263-9. PubMed ID: 23040326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing first-line treatment options for patients with advanced NSCLC.
    Wakelee H; Belani CP
    Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer.
    Gridelli C; Brodowicz T; Langer CJ; Peterson P; Islam M; Guba SC; Moore P; Visseren-Grul CM; Scagliotti G
    Clin Lung Cancer; 2012 Sep; 13(5):340-6. PubMed ID: 22266043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
    Gridelli C; Maione P; Rossi A; De Marinis F
    Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extending survival of stage IV non-small cell lung cancer.
    Carnio S; Novello S; Mele T; Levra MG; Scagliotti GV
    Semin Oncol; 2014 Feb; 41(1):69-92. PubMed ID: 24565582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategy for treatment of metastatic non-small cell lung cancer.
    Berhoune M; Banu E; Scotte F; Prognon P; Oudard S; Bonan B
    Ann Pharmacother; 2008 Nov; 42(11):1640-52. PubMed ID: 18957625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of advanced non-small-cell lung cancer in the elderly.
    Gridelli C; Maione P; Rossi A; Ferrara ML; Castaldo V; Palazzolo G; Mazzeo N
    Lung Cancer; 2009 Dec; 66(3):282-6. PubMed ID: 19879012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
    Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
    Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of chemotherapy for patients with advanced non-small cell lung cancer.
    Pennell NA
    Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS46-50. PubMed ID: 22614966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC).
    Langer CJ; Mok T; Postmus PE
    Cancer Treat Rev; 2013 May; 39(3):252-60. PubMed ID: 22703830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gemcitabine in the first line therapy of advanced and metastatic non-small-cell lung carcinoma (NSCLC): review of the results of phase III studies].
    Langer F; Helsberg K; Schütte WH; Leschinger MI
    Onkologie; 2005 Mar; 28 Suppl 1():1-28. PubMed ID: 15802886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy for metastatic non-small cell lung cancer].
    Pérol M; Moro-Sibilot D
    Rev Mal Respir; 2005 Dec; 22(6 Pt 2):8S131-6. PubMed ID: 16340849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.